PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) major shareholder Euclidean Capital Llc sold 39,638 shares of the stock in a transaction that occurred on Wednesday, June 9th. The shares were sold at an average price of $33.64, for a total transaction of $1,333,422.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Euclidean Capital Llc also recently made the following trade(s):
- On Monday, June 7th, Euclidean Capital Llc sold 30,721 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $33.62, for a total transaction of $1,032,840.02.
PMVP stock traded up $1.67 on Friday, hitting $34.40. 208,178 shares of the company’s stock traded hands, compared to its average volume of 176,323. PMV Pharmaceuticals, Inc. has a 1-year low of $26.38 and a 1-year high of $63.22. The firm has a market cap of $1.55 billion and a PE ratio of -13.64. The stock’s fifty day moving average is $33.44.
PMV Pharmaceuticals (NASDAQ:PMVP) last released its earnings results on Friday, May 14th. The company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). Equities analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.22 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its holdings in shares of PMV Pharmaceuticals by 2,421.3% during the first quarter. JPMorgan Chase & Co. now owns 935,390 shares of the company’s stock valued at $30,765,000 after acquiring an additional 898,291 shares during the period. Personal CFO Solutions LLC acquired a new stake in shares of PMV Pharmaceuticals during the first quarter valued at approximately $28,111,000. BlackRock Inc. raised its holdings in shares of PMV Pharmaceuticals by 148.1% during the fourth quarter. BlackRock Inc. now owns 1,345,015 shares of the company’s stock valued at $82,731,000 after acquiring an additional 802,977 shares during the period. Avoro Capital Advisors LLC raised its holdings in shares of PMV Pharmaceuticals by 27.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,350,267 shares of the company’s stock valued at $130,536,000 after acquiring an additional 500,267 shares during the period. Finally, Deerfield Management Company L.P. Series C raised its holdings in shares of PMV Pharmaceuticals by 126.3% during the first quarter. Deerfield Management Company L.P. Series C now owns 423,680 shares of the company’s stock valued at $13,935,000 after acquiring an additional 236,488 shares during the period. 88.63% of the stock is owned by institutional investors and hedge funds.
Picking the right “investment of the decade” can transform your life…
Today, the Wall Street legend who picked the last “investment of the decade”… months (even years) before his peers… will finally reveal his new #1 pick for the 2020s.
It’s not 5G, artificial intelligence, EVs, or clean energy. The answer will surprise you.
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company’s lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function.
Further Reading: How to calculate compound interest
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What is the Ex-Dividend Date in Investing?
7 Precious Metals Stocks That Will Keep Your Portfolio On Trend
The growing acceptance of cryptocurrency is beginning to make mainstream investors rethink their idea of “store of value.” The trendy possibilities of Bitcoin, Ethereum, and any of the dozens of altcoins that exist on the blockchain are trending like the latest fashion.
However, the thing about fashion is that the more things change the more things stay the same. Just like the simple black dress that won’t go out of fashion, the same can be said for precious metals stocks. One way to think about it would be to say that the existence of a growing cryptocurrency market doesn’t change the value of precious metals.
Precious metals have long been known to be a safe-haven asset in times of market volatility and economic crisis. In fact, during the Covid-19 pandemic, gold prices surged about 30% breaking the $2,000 mark for the first time in its history. This was at a time when the prices of many cryptocurrencies were falling.
And precious metals have also been seen as a hedge against inflation, which seems like more of a certainty with the Federal Reserve’s pledge to keep interest rates at historically low rates into 2023.
Whether you’re looking to take your first steps at crafting a precious metals portfolio or if you want to fine-tune the one you have, we believe this special presentation is a good place to start your research. We’ve identified seven precious metals stocks that look to retain their allure in 2021.
View the “7 Precious Metals Stocks That Will Keep Your Portfolio On Trend”.